Yan Leyfman Reflects on the New ALS Biomarker Research
Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“New ALS biomarker research
Using the Olink Explore 3072 platform, researchers analyzed plasma proteomics in patients with ALS and controls:
– 33 proteins were differentially abundant in ALS
– Findings replicated in an independent cohort
– Machine learning model diagnosed ALS with 98.3% accuracy
– Biomarkers revealed disease processes years before symptoms
– Plasma proteins may serve as a reliable biomarker for ALS, offering insights into its prodromal phase and potential for earlier diagnosis.”
Title: A plasma proteomics-based candidate biomarker panel predictive of amyotrophic lateral sclerosis
Authors: Ruth Chia, Ruin Moaddel, Justin Y. Kwan, Memoona Rasheed, Paola Ruffo, Natalie Landeck, Paolo Reho, Rosario Vasta, Andrea Calvo, Cristina Moglia, Antonio Canosa, Umberto Manera, Allison Snyder, Sara Saez-Atienzar, Maurizio Grassano, Maura Brunetti, Federico Casale, Anindita Ray, Kumar Arvind, Betul Comertpay, Min Zhu, J. Raphael Gibbs, The American Genome Center, Camille Alba, Bryan J. Traynor
Read The Full Article at Nature Medicine.
More posts featuring Yan Leyfman on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023